2023
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2015
GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology
Deftereos G, Ramirez A, Silverman J, Krishnamurti U. GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology. The American Journal Of Surgical Pathology 2015, 39: 1282-1289. PMID: 26274030, DOI: 10.1097/pas.0000000000000505.Peer-Reviewed Original ResearchConceptsTriple-negative breast carcinomaGCDFP-15Breast carcinomaCytology casesGynecologic malignanciesER expressionHistologic subtypeExpression correlatesMetastatic gynecologic malignanciesMetastatic breast carcinomaNegative breast carcinomaPrimary breast carcinomaStaining scoresNegative carcinomasOvarian carcinomaImmunohistochemistry expressionHistology casesMammaglobinCarcinomaIntensity scoresGATA3 expressionSubtypesGATA3Cancer cellsBreast